# A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

> **NCT04671615** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 559 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** palbociclib

## Key facts

- **NCT ID:** NCT04671615
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-06
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-11-30
- **Target enrollment:** 559 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671615, "A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04671615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*